• 1
    Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2011.
  • 2
    CDC. CDC grand rounds: Prescription drug overdoses—A U.S. epidemic. MMWR Morb Mortal Wkly Rep. 2012; 61:1013.
  • 3
    Feillin D, O'Connor P. Office-based treatment of opioid-dependent patients. N Engl J Med. 2002; 347:817823.
  • 4
    Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003; 349:949958.
  • 5
    Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000; 343:12901297.
  • 6
    Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. Arch Gen Psychiat. 2011; 68:12381246.
  • 7
    Subramaniam GA, Warden D, Minhajuddin A, et al. Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth. J Am Acad Child Adolesc Psychiatry. 2011; 50:11201128.
  • 8
    Fareed A, Vayalapalli S, Casarella J, Drexler K. Effect of buprenorphine dose on treatment outcome. J Addict Dis. 2012; 31:818.
  • 9
    Equianalgesic Chart. Accessed June 2010.
  • 10
    Benningfield MM, Dietrich MS, Jones HE, et al. Opioid dependence during pregnancy: Relationships of anxiety and depression symptoms to treatment outcomes. Addiction. 2012; 107(Suppl 1):7482.
  • 11
    Gerra G, Borella F, Zaimovic A, et al. Buprenorphine versus methadone for opioid dependence: Predictor variables for treatment outcome. Drug Alcohol Depend. 2004; 75:3745.
  • 12
    Hillhouse M, Canamar CP, Doraimani G, et al. Participant characteristics and buprenorphine dose. Am J Drug Alcohol Abuse. 2011; 37:453459.
  • 13
    Martin PR, Patel S, Swift RM. Pharmacology of drugs of abuse. In: Golan D, Tashjian AH, Armstrong EJ, Armstrong A, eds. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy, 3rd edn, pp. 284309. Philadelphia: Lippincott Williams & Wilkins; 2012.
  • 14
    Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial. JAMA. 2006; 295:20032017.